Notícias

VEEV's strong Q1, growing Vault CRM migrations and AI expansion support growth, though life sciences CRM market saturation poses risks.

NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offering upside despite near-term losses.

AMN Healthcare acquires Jaide Health to add AI-powered interpretation and translation, widening language access across more healthcare touchpoints.

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.26%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.12%. June E-mini S&P futures (ESM26 ) fell -0.36%, and June E-mini Nasdaq futures...

The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures (ESM26 ) are down -0.25%, and June E-mini Nasdaq futures...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...

Pre-Market Stock Futures: Futures are trading higher after the bulls tried to rally stocks on Monday, after the drubbing they took on Friday, and it looks the same way today. While it was a partial victory on Monday, by the close, the huge gains from the morning were cut in half, and the Dow Jones ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Cerebras Systems, Cleveland-Cliffs, Equity Residential, FuelCell Energy, Lennar, Luckin Coffee, Toll Brothers, and More

With a net profit margin of 16.85%, West Pharmaceutical Services, Inc. (NYSE:WST) is included among the 10 Most Profitable Dividend Stocks to Invest In Now. Wolfe Research analyst Mike Polark upgraded West Pharmaceutical Services, Inc. (NYSE:WST) to Outperform from Peer Perform on June 2. He also assigned a $375 price target to the stock. The analyst […]

DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.

MMSI leans on therapeutic strength, an oncology acquisition and a new stent launch, but tariffs, OEM weakness and China pressure shadow 2026.

Natera teams with CytoDyn to track ctDNA in CLOVER Phase 2, using Signatera to map leronlimab response in metastatic colorectal cancer.

West Pharmaceutical Services Inc (NYSE:WST) is one of the best stocks to buy according to billionaire Bill Gates. WST stock is up around 14% year-to-date and has gained nearly 50% over the past year. Analysts still see upside potential in the stock. On May 31, Wolfe Research initiated coverage of West Pharmaceutical Services Inc (NYSE:WST) […]

The updated analyst narrative for West Pharmaceutical Services now reflects a fair value estimate of US$352.36 per share, up from US$349.85. This refinement sits alongside fresh company guidance for Q2 2026 net sales, a recent buyback of 1,222,019 shares for US$297.65 million, and an announced leadership transition planned for the second half of 2026. Read on to see how these moving parts fit together and how you can keep track of the evolving story. Wall Street's queuing for one rocket...

Cooper Companies beats Q2 EPS and sales estimates as CooperVision and CooperSurgical hit record revenues, even with a GAAP loss from recall litigation.

Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.

GEHC wins FDA clearance for AI-powered radiation planning software, adding new clinical models and a pathway for faster future updates.

DXCM banks on CGM market growth, expanding international demand and strong Q1 momentum, though competitive pressures remain a key risk.

Veeva Systems beats Q1 earnings and revenue estimates, raises fiscal 2027 guidance, and expands AI offerings as adoption of its software platforms expands.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SYK launches TPX HD, a small bone power tool built for complex revisions, MIS and oral maxillofacial cases with higher torque and speed.

PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.

AMN Healthcare is riding MSP momentum, labor disruption demand and AI platforms, yet faces pricing pressure and post-disruption volatility.

NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG data to speed ECoG review and insights.

Natera teams with Diakonos to use Signatera MRD testing in a refractory melanoma immunotherapy trial, tracking ctDNA to gauge response.

PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.

Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HQY tops Q1 FY27 EPS and revenue estimates as HSA accounts and assets climb, and guidance for FY27 revenues and adjusted EPS rises.

NTRA upgrades Panorama NIPT with SNP-informed deep sequencing, validated for low fetal fraction to cut no-calls and boost reliable prenatal results.

SYK launches Pangea Plating System in Europe, completing its first London case as it broadens trauma care solutions for many fractures.